These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18187806)

  • 1. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.
    Sissung TM; Danesi R; Price DK; Steinberg SM; de Wit R; Zahid M; Gaikwad N; Cavalieri E; Dahut WL; Sackett DL; Figg WD; Sparreboom A
    Mol Cancer Ther; 2008 Jan; 7(1):19-26. PubMed ID: 18187806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.
    Pastina I; Giovannetti E; Chioni A; Sissung TM; Crea F; Orlandini C; Price DK; Cianci C; Figg WD; Ricci S; Danesi R
    BMC Cancer; 2010 Sep; 10():511. PubMed ID: 20875115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms?
    Brandi G; de Rosa F; Danesi R; Montini GC; Biasco G
    Eur Urol; 2008 Oct; 54(4):938-41. PubMed ID: 18657896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
    Rizzo R; Spaggiari F; Indelli M; Lelli G; Baricordi OR; Rimessi P; Ferlini A
    Breast Cancer Res Treat; 2010 Nov; 124(2):593-8. PubMed ID: 20632082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens.
    Cussenot O; Azzouzi AR; Nicolaiew N; Fromont G; Mangin P; Cormier L; Fournier G; Valeri A; Larre S; Thibault F; Giordanella JP; Pouchard M; Zheng Y; Hamdy FC; Cox A; Cancel-Tassin G
    J Clin Oncol; 2007 Aug; 25(24):3596-602. PubMed ID: 17704407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
    Sissung TM; Danesi R; Kirkland CT; Baum CE; Ockers SB; Stein EV; Venzon D; Price DK; Figg WD
    J Clin Endocrinol Metab; 2011 Feb; 96(2):E368-72. PubMed ID: 21106711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 1B1-mediated estrogen metabolism results in estrogen-deoxyribonucleoside adduct formation.
    Belous AR; Hachey DL; Dawling S; Roodi N; Parl FF
    Cancer Res; 2007 Jan; 67(2):812-7. PubMed ID: 17234793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interethnic differences of cytochrome P450 gene polymorphisms may influence outcome of taxane therapy in Roma and Hungarian populations.
    Szalai R; Ganczer A; Magyari L; Matyas P; Bene J; Melegh B
    Drug Metab Pharmacokinet; 2015 Dec; 30(6):453-6. PubMed ID: 26507668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer.
    Tanaka Y; Sasaki M; Kaneuchi M; Shiina H; Igawa M; Dahiya R
    Biochem Biophys Res Commun; 2002 Aug; 296(4):820-6. PubMed ID: 12200121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance.
    Martinez VG; O'Connor R; Liang Y; Clynes M
    Br J Cancer; 2008 Feb; 98(3):564-70. PubMed ID: 18212750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness.
    Cicek MS; Liu X; Casey G; Witte JS
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2173-7. PubMed ID: 16172228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP1A1 and CYP1B1 polymorphisms and their association with estradiol and estrogen metabolites in women who are premenopausal and perimenopausal.
    Sowers MR; Wilson AL; Kardia SR; Chu J; McConnell DS
    Am J Med; 2006 Sep; 119(9 Suppl 1):S44-51. PubMed ID: 16949388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
    Figg WD; Li H; Sissung T; Retter A; Wu S; Gulley JL; Arlen P; Wright JJ; Parnes H; Fedenko K; Latham L; Steinberg SM; Jones E; Chen C; Dahut W
    BJU Int; 2007 May; 99(5):1047-55. PubMed ID: 17437439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients.
    Vasile E; Tibaldi C; Leon GL; D'Incecco A; Giovannetti E
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1189-94. PubMed ID: 25504507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme.
    Bournique B; Lemarié A
    Drug Metab Dispos; 2002 Nov; 30(11):1149-52. PubMed ID: 12386117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP1B1 gene in endometrial cancer.
    Sasaki M; Kaneuchi M; Fujimoto S; Tanaka Y; Dahiya R
    Mol Cell Endocrinol; 2003 Apr; 202(1-2):171-6. PubMed ID: 12770747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between genetic polymorphism of cytochrome P450-1B1, sulfotransferase 1A1, catechol-o-methyltransferase and tobacco exposure in breast cancer risk.
    Saintot M; Malaveille C; Hautefeuille A; Gerber M
    Int J Cancer; 2003 Nov; 107(4):652-7. PubMed ID: 14520706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of CYP1B1 gene polymorphisms and the positive expression of estrogen alpha and estrogen beta with endometrial cancer risk.
    Zhu ZY; Mu YQ; Fu XM; Li SM; Zhao FX
    Eur J Gynaecol Oncol; 2011; 32(2):188-91. PubMed ID: 21614911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the influence of polymorphic variants CYP1A1 2B, CYP1B1 2, CYP3A4 1B, GSTM1 0, and GSTT1 0 in prostate cancer.
    Rodrigues IS; Kuasne H; Losi-Guembarovski R; Fuganti PE; Gregório EP; Kishima MO; Ito K; de Freitas Rodrigues MA; de Syllos Cólus IM
    Urol Oncol; 2011; 29(6):654-63. PubMed ID: 20884258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Val432Leu polymorphism of the CYP1B1 gene is associated with differences in estrogen metabolism and bone density.
    Napoli N; Rini GB; Serber D; Giri T; Yarramaneni J; Bucchieri S; Camarda L; Di Fede G; Camarda MR; Jain S; Mumm S; Armamento-Villareal R
    Bone; 2009 Mar; 44(3):442-8. PubMed ID: 18977467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.